Bristol Myers Squibb (CELG-RI) Dividends payables (2009 - 2015)
Bristol Myers Squibb (CELG-RI) posted quarterly Dividends payables of $655.0 million for Q4 2015, up 1.55% YoY from $645.0 million in Q4 2014, and up 2.99% sequentially from $636.0 million in Q3 2015.
Bristol Myers Squibb (CELG-RI) Dividends payables (2009 - 2015) Analysis & Trends
Bristol Myers Squibb has disclosed Dividends payables across 7 years of filings, most recently posting $655.0 million for Q4 2015.
- In Q4 2015, Dividends payables rose 1.55% year-over-year to $655.0 million; the TTM figure through Dec 2015 stood at $655.0 million (up 1.55% YoY), while the FY2015 annual figure was $655.0 million, up 1.55% from the prior year.
- Dividends payables climbed to $655.0 million in Q4 2015, from $636.0 million in the prior quarter.
- Over the last five years, Dividends payables for CELG-RI reached as high as $655.0 million in Q4 2015 and fell as low as $578.0 million in Q1 2011.
- The 5-year median for Dividends payables is $608.5 million (2012), against an average of $612.2 million.
- The widest YoY moves for Dividends payables: up 4.62% in 2013, down 1.34% in 2013.
- A 5-year view of Dividends payables shows it stood at $597.0 million in 2011, then gained by 1.51% to $606.0 million in 2012, then increased by 4.62% to $634.0 million in 2013, then climbed by 1.74% to $645.0 million in 2014, then increased by 1.55% to $655.0 million in 2015.
- According to Business Quant data, Dividends payables over the past three periods registered $655.0 million, $636.0 million, and $634.0 million for Q4 2015, Q3 2015, and Q2 2015 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Dividends payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | - |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | - |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 2.14 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | - |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | - |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Bristol Myers Squibb | 244.56 Mn | -10.21 Bn | 8.07 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2015 | 655.00 Mn |
| Sep 30, 2015 | 636.00 Mn |
| Jun 30, 2015 | 634.00 Mn |
| Mar 31, 2015 | 633.00 Mn |
| Dec 31, 2014 | 645.00 Mn |
| Sep 30, 2014 | 623.00 Mn |
| Jun 30, 2014 | 621.00 Mn |
| Mar 31, 2014 | 619.00 Mn |
| Dec 31, 2013 | 634.00 Mn |
| Sep 30, 2013 | 611.00 Mn |
| Jun 30, 2013 | 606.00 Mn |
| Mar 31, 2013 | 601.00 Mn |
| Dec 31, 2012 | 606.00 Mn |
| Sep 30, 2012 | 596.00 Mn |
| Jun 30, 2012 | 598.00 Mn |
| Mar 31, 2012 | 593.00 Mn |
| Dec 31, 2011 | 597.00 Mn |
| Sep 30, 2011 | 578.00 Mn |
| Jun 30, 2011 | 579.00 Mn |
| Mar 31, 2011 | 578.00 Mn |